Brinda Emu, MD

Associate Professor Term

Research Departments & Organizations

Internal Medicine: Infectious Diseases

Cancer Immunology

Office of Cooperative Research

Research Interests

Aging, Premature; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; Head and Neck Neoplasms; Hematologic Neoplasms; HIV; Immune Evasion; Immune Reconstitution; Immune System; Immunocompromised Host; Infectious Disease Medicine; Thoracic Neoplasms; T-Lymphocytes

Research Summary

Our laboratory is focused on understanding the persistent deficits in the immune system in individuals with HIV infection, despite the advent of successful antiretroviral therapy. Individuals with HIV, even after effective control of HIV replication, remain at higher risk for some non-AIDS related clinical conditions, including cardiovascular disease, metabolic disorders, and certain malignancies. Our research focuses on understanding those aspects of the immune system that remain impaired despite effective treatment of HIV infection. In addition, we hope to elucidate which of these persistent immunologic aberrancies are associated with clinical disease. In this way, we hope to elucidate important biomarkers for clinical risk.

Our laboratory will also be specifically focused on understanding the pathogenesis, incidence, presentation, and prognosis of cancers in the setting of HIV infection. Individuals with HIV remain at risk for particular malignancies, despite effective control of HIV replication. The malignancies where continue increased risk is seen are non-Hodgkin's lymphoma, Hodgkin's lymphoma, HPV-related cancers, hepatocellular carcinoma, and lung cancer. We will be studying biomarkers that will allow for early diagnosis of patients at increased risk, as well as focusing on the pathologic, molecular, and genetic differences of these cancers in HIV infected individuals compared to individuals without HIV infection.

Specialized Terms: HIV and aging; Immune dysfunction in setting of HIV infection

Extensive Research Description

  • Evaluation of different T cell phenotypes/function across different ages of HIV-infected indivdiuals on antiretroviral therapy, compared with HIV-uninfected individuals
  • Impact of T cell aberrancies on incidence of clinical disease (focus on cardiovascular and oncology outcomes)
  • Evaluating immunologic parameters of individuals with cancer diagnoses in setting of HIV infection

Clinical Trials

Conditions Study Title
HIV/AIDS Mechanisms of HIV latency
HIV/AIDS, Immune System, Infectious Diseases Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Edit this profile

Contact Info

Brinda Emu, MD
Mailing Address
Infectious DiseasesPO Box 208022
New Haven, CT 06520-8022